Trial Profile
Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 weeks.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs ORM 12741 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms ALPO
- Sponsors Orion; Orion Pharma
- 26 Sep 2013 Results presented at the 21st World Congress of Neurology.
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 20 Mar 2013 Results were presented at the American Academy of Neurology's Annual Meeting, according to an Orion Corporation media release.